Current Treatment Options in Cold Agglutinin Disease: B-Cell Directed or Complement Directed Therapy?

Area of Science:

• Hematology
• Immunology
• Pharmacology

Background:

• Cold agglutinin disease (CAD) pathogenesis involves clonal B-cell lymphoproliferation and complement-mediated hemolysis.
• These two key steps in CAD pathogenesis represent distinct therapeutic targets.

Approach:

• This review focuses on two successful therapeutic strategies for CAD.
• Evaluates bendamustine plus rituximab (B+R) as a B-cell-directed therapy.
• Examines sutimlimab, an anti-C1s monoclonal antibody, as a complement-targeting therapy.

Key Points:

• Bendamustine plus rituximab demonstrates high response rates, complete responses, and long duration but is slow-acting and toxic.
• Sutimlimab shows high efficacy, rapid action, and low toxicity, but may require indefinite treatment and has high costs.
• Neither therapy directly addresses circulatory symptoms effectively.

Conclusions:

• Both B+R and sutimlimab are effective treatments for cold agglutinin disease.
• Treatment selection for CAD patients necessitates individual assessment based on efficacy, toxicity, duration, and cost.